These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Multiple sclerosis: new measures to monitor the disease. Filippi M; Rocca MA Lancet Neurol; 2013 Jan; 12(1):12-3. PubMed ID: 23237892 [No Abstract] [Full Text] [Related]
23. Interferon beta-1b for the treatment of multiple sclerosis. Petri T; Weber-Diehl F J Biotechnol; 1995 Nov; 43(1):74-5. PubMed ID: 8573325 [No Abstract] [Full Text] [Related]
24. Natalizumab and PML: a risky business? Clifford DB Gut; 2008 Oct; 57(10):1347-9. PubMed ID: 18791114 [No Abstract] [Full Text] [Related]
25. Natalizumab (TYSABRI) and multiple sclerosis. With longer follow-up: even more toxic than suspected. Prescrire Int; 2015 Mar; 24(158):65-7. PubMed ID: 25897454 [TBL] [Abstract][Full Text] [Related]
26. Editorial: Licensing and Use of New Therapies in MS: Where Are We Going? Hurwitz B Int MS J; 2005 Aug; 12(2):39-41. PubMed ID: 16417813 [No Abstract] [Full Text] [Related]
27. [Neuromyelitis optica--an important differential diagnosis for multiple sclerosis]. Holbech JV; Falah M Ugeskr Laeger; 2009 Nov; 171(49):3622-3. PubMed ID: 19954705 [TBL] [Abstract][Full Text] [Related]
29. Neuromyelitis optica is a variant of multiple sclerosis. Galetta SL; Bennett J Arch Neurol; 2007 Jun; 64(6):901-3. PubMed ID: 17562943 [No Abstract] [Full Text] [Related]
30. [Natalizumab in the treatment of multiple sclerosis]. Horga A; Horga de la Parte JF Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741 [TBL] [Abstract][Full Text] [Related]
31. Is neuromyelitis optica eyeing a distinct path from multiple sclerosis? Glisson CC; Galetta SL Arch Ophthalmol; 2008 Jan; 126(1):128-9. PubMed ID: 18195231 [No Abstract] [Full Text] [Related]
34. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Cutter GR; Stüve O Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045 [TBL] [Abstract][Full Text] [Related]
35. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Khalili K; White MK; Lublin F; Ferrante P; Berger JR Neurology; 2007 Mar; 68(13):985-90. PubMed ID: 17389301 [TBL] [Abstract][Full Text] [Related]
36. [Neuromyelitis optica(Devic disease) and optic-spinal form multiple sclerosis]. Miyazawa I; Fujihara K; Itoyama Y No To Shinkei; 2001 Oct; 53(10):901-10. PubMed ID: 11725499 [No Abstract] [Full Text] [Related]
37. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229 [TBL] [Abstract][Full Text] [Related]
38. Natalizumab for relapsing remitting multiple sclerosis. Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773 [TBL] [Abstract][Full Text] [Related]
39. Neuromyelitis optica: what it is and what it might be. Weinshenker BG Lancet; 2003 Mar; 361(9361):889-90. PubMed ID: 12648964 [No Abstract] [Full Text] [Related]
40. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]